Published on February 17, 2020

Amsterdam, Netherlands and Hoboken, New Jersey:  February 17, 2020: Castor, a health-tech company that enables medical researchers to capture standardized data to support data driven medical decision making, announced that it will provide free access to its data capture system to all COVID-19 research projects.

On January 30, 2020, the World Health Organization (WHO) declared the new airborne contagious coronavirus (SARS-CoV-2 a.k.a 2019-nCoV), that causes the disease dubbed COVID-19, a Public Health Emergency of International Concern. The WHO is providing technical guidance on how to conduct useful early investigations and has highlighted the need to assemble large amounts of accurate and usable data as quickly as possible.

Castor has developed and made available ready-for-use electronic Case Report Forms (eCRFs) based on the WHO standard CRFs, to help researchers start their study or registry in less than an hour, ensuring they capture high quality data to help drive the global research effort.

By ensuring researchers capture standardized data on Castor’s clinical data platform, clinical data from around the world can be easily aggregated. This approach can accelerate the work of researchers who are trying to understand the virus and disease. 

Commenting on the initiative, Castor’s CEO Derk Arts, MD, PhD, said: “When novel strains of viruses like the Coronavirus emerge, data quickly becomes our most valuable asset. On behalf of the team, I am proud to announce that Castor is joining the fight against COVID-19 by making our data capture platform available for free for all COVID-19 research projects.

“A standardized approach in collecting clinical data is critical in order  to better understand the natural history of disease and describe clinical phenotypes and treatment interventions (i.e. clinical characterization). For a global data collection effort to be truly successful, we need to go beyond standardized forms. The threshold for capturing these datasets should be as low as possible, to ensure anyone is willing and able to contribute valuable data.”

Castor encourages all COVID-19 researchers in need of standardized, high quality data to submit for a free billing code via [email protected], to start their studies by registering here, and to visit their online academy to become familiar with the platform. The WHO-defined CRFs can be downloaded here.

Castor’s Electronic Data Capture (EDC) system enables every researcher worldwide to easily capture and integrate medical research data from any source in real-time, including clinicians, patients, devices and wearables. Researchers on the platform generate vast amounts of data from traditional and decentralized trials, and Castor recently reached milestones of 130,000,000 data points and 1,400,000 enrolled patients.

ENDS 

For more information about Castor please contact:

Castor
John Ambrose, Esq
Head of Marketing
[email protected]

Media & IR Enquiries
Optimum Strategic Communications 
Mary Clark/ Hollie Vile/Manel Mateus
[email protected]

Tel: +44 (0) 20 3922 1906

NOTES TO EDITORS

About Castor 

Based in Amsterdam, The Netherlands and New Jersey, US, Castor is an international health-tech company founded by CEO Derk Arts, MD, PhD to leverage machine readable data to increase clinical trial efficiency. Castor’s Electronic Data Capture (EDC) system enables every researcher worldwide to easily capture and integrate medical research data from any source in real-time, including clinicians, patients, devices, wearables, and EHR systems.

More than 37,000 researchers across 90 countries are using Castor to supercharge their research. Castor’s platform has supported more than 4,000 commercial and academic studies that cover a broad range of disease areas including diabetes, cardiovascular disease, rare diseases, and oncology. Researchers on the platform generate vast amounts of data from traditional and decentralized trials, and Castor recently reached milestones of 130,000,000 data points and 1,400,000 enrolled patients. Castor’s goal is to make the world’s research data reusable, enabling AI-driven clinical trials, and ultimately creating a future in which they maximize the impact of data through reuse.

In 2018 Castor raised $6.25m in funding from early-stage investor INKEF Capital in the Netherlands.

Website: castoredc2.staging.wpengine.com

Twitter: @Castor

LinkedIn: linkedin.com/company/ciwit-b-v-